Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock

Company Overview - Gilead Sciences Inc. is a biopharmaceutical company focused on researching, developing, and selling innovative medicines for life-threatening diseases, including HIV/AIDS, viral hepatitis, cancer, COVID-19, and inflammation [1] Q3 2025 Earnings Expectations - Gilead is set to report its Q3 2025 earnings on November 5, with Wall Street analysts expecting an EPS of $2.15, an increase from $2.02 in the same period last year [2] - Quarterly revenue is anticipated to be $7.41 billion, a decrease from $7.54 billion a year earlier [2] Recent Performance - In Q2 2025, Gilead reported adjusted EPS of $2.01, exceeding the consensus estimate of $1.94, and revenues of $7.08 billion, surpassing the consensus of $6.94 billion [4] - The company experienced strong growth driven by products such as Biktarvy, Descovy, Trodelvy, and Livdelzi [5] Future Guidance - For the full year 2025, Gilead expects non-GAAP diluted EPS to be in the range of $7.95 to $8.25, indicating an optimistic outlook for revenue and earnings growth [5] Stock Performance and Dividends - Gilead Sciences' stock price has ranged from $78.36 to $121.82 over the past 52 weeks [3] - The company has a dividend yield of 2.73%, having paid $3.16 per share in dividends over the last 12 months [3]